Evidence map›Paper›PMID 42403387›Full record

ArticleFrontiers in pediatrics2026

Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series.

Zelei He, Yuanyuan Wu, Hongmei Yang, Yijuan Li, Lingling Xu

Abstract readCase Reports
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zelei He *Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Yuanyuan Wu *Department of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Hongmei YangDepartment of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Yijuan LiDepartment of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
Lingling XuDepartment of Pediatrics, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by pathogenic Cases presentation: Two Chinese male patients with classic FD phenotypes and proteinuria were treated with agalsidase beta (1 mg/kg every two weeks). Case 1 (last followed up at age 34, Conclusions: In these two cases, agalsidase beta was well-tolerated and associated with stabilization of renal and cardiac function. The management of proteinuria required concomitant RAAS inhibition. Family cascade screening remains critical for early diagnosis.

Indexed as

agalsidase betacase seriesChinese populationenzyme replacement therapyfabry diseaserenal transplantation

Identifiers

PMID42403387
PMCPMC13329935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.